Skip to main content

Advertisement

SpringerLink
Log in

Metabolic Memory and Chronic Diabetes Complications: Potential Role for Epigenetic Mechanisms

  • Treatment of Type 1 Diabetes (D Dabelea, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Recent estimates indicate that diabetes mellitus currently affects more than 10 % of the world’s population. Evidence from both the laboratory and large scale clinical trials has revealed that prolonged hyperglycemia induces chronic complications which persist and progress unimpeded even when glycemic control is pharmaceutically achieved via the phenomenon of metabolic memory. The epigenome is comprised of all chromatin modifications including post translational histone modification, expression control via miRNAs and the methylation of cytosine within DNA. Modifications of these epigenetic marks not only allow cells and organisms to quickly respond to changing environmental stimuli but also confer the ability of the cell to “memorize” these encounters. As such, these processes have gained much attention as potential molecular mechanisms underlying metabolic memory and chronic diabetic complications. Here we present a review of the very recent literature published pertaining to this subject.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

    PubMed  CAS  Google Scholar 

  2. • Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–25. This manuscript summarizes many years of work and documented a unifying mechanism that causes diabetic complications.

    PubMed  CAS  Google Scholar 

  3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–12.

    PubMed  CAS  Google Scholar 

  4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.

  5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–12.

    PubMed  CAS  Google Scholar 

  6. Gaede PH, Jepsen PV, Larsen JN, Jensen GV, Parving HH. Pedersen OB [The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. Ugeskr Laeger. 2003;165:2658–61.

    PubMed  Google Scholar 

  7. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

    PubMed  CAS  Google Scholar 

  8. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.

    PubMed  Google Scholar 

  9. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381–9.

  10. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67.

    Google Scholar 

  11. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med. 2009;169:1307–16.

    PubMed  Google Scholar 

  12. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30.

    PubMed  Google Scholar 

  13. Patel A, Macmahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    PubMed  CAS  Google Scholar 

  14. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care. 2001;24:942–5.

    PubMed  CAS  Google Scholar 

  15. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–92.

    PubMed  Google Scholar 

  16. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:844–46.

    PubMed  Google Scholar 

  17. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, et al. Cost-effectiveness of intensified vs conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care. 2008;31:1510–15.

    PubMed  Google Scholar 

  18. • Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808–12. This manuscript provided the first evidence of the metabolic memory phenomenon.

    PubMed  CAS  Google Scholar 

  19. Hammes HP, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Invest Ophthalmol Vis Sci. 1993;34:2092–6.

    PubMed  CAS  Google Scholar 

  20. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes. 2003;52:818–23.

    PubMed  CAS  Google Scholar 

  21. Kowluru RA, Chakrabarti S, Chen S. Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-κB) in the retina. Acta Diabetol. 2004;41:194–9.

    PubMed  CAS  Google Scholar 

  22. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A. 1990;87:404–8.

    PubMed  CAS  Google Scholar 

  23. Li SL, Reddy MA, Cai Q, Meng L, Yuan H, Lanting L, et al. Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes. 2006;55:2611–9.

    PubMed  CAS  Google Scholar 

  24. •• Olsen AS, Sarras MP, Jr., Leontovich A, Intine RV. Heritable transmission of diabetic metabolic memory in zebrafish correlates with DNA hypomethylation and aberrant gene expression. Diabetes. 2012;61(2):485–91. This manuscript was the first to document that aberrant DNA methylation induced by hyperglycemia is maintained in the metabolic memory state. Additionally, through using the zebrafish model the epigenetic control of gene expression can be separated from the previous hyperglycemic background.

  25. Ihnat MA, Thorpe JE, Kamat CD, Szabo C, Green DE, Warnke LA, et al. Reactive oxygen species mediate a cellular 'memory' of high glucose stress signalling. Diabetologia. 2007;50:1523–31.

    PubMed  CAS  Google Scholar 

  26. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410–5.

    PubMed  CAS  Google Scholar 

  27. Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 2010;463:474–84.

    PubMed  CAS  Google Scholar 

  28. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(Suppl):245–54.

    PubMed  CAS  Google Scholar 

  29. Jirtle RL, Sander M, Barrett JC. Genomic imprinting and environmental disease susceptibility. Environ Health Perspect. 2000;108:271–8.

    PubMed  CAS  Google Scholar 

  30. Dolinoy DC, Jirtle RL. Environmental epigenomics in human health and disease. Environ Mol Mutagen. 2008;49:4–8.

    PubMed  CAS  Google Scholar 

  31. Morgan DK, Whitelaw E. The case for transgenerational epigenetic inheritance in humans. Mamm Genome. 2008;19:394–7.

    PubMed  Google Scholar 

  32. Blomen VA, Boonstra J. Stable transmission of reversible modifications: maintenance of epigenetic information through the cell cycle. Cell Mol Life Sci. 2010.

  33. Bogdanovic O, Veenstra GJ. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma. 2009;118:549–65.

    PubMed  CAS  Google Scholar 

  34. Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem. 2010;79:155–79.

    PubMed  CAS  Google Scholar 

  35. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.

    PubMed  CAS  Google Scholar 

  36. Gluckman PD, Hanson MA, Beedle AS. Non-genomic transgenerational inheritance of disease risk. Bioessays. 2007;29:145–54.

    PubMed  CAS  Google Scholar 

  37. Bjornsson HT, Fallin MD, Feinberg AP. An integrated epigenetic and genetic approach to common human disease. Trends Genet. 2004;20:350–8.

    PubMed  CAS  Google Scholar 

  38. Whitelaw NC, Whitelaw E. Transgenerational epigenetic inheritance in health and disease. Curr Opin Genet Dev. 2008;18:273–9.

    PubMed  CAS  Google Scholar 

  39. Rando OJ. Combinatorial complexity in chromatin structure and function: revisiting the histone code. Curr Opin Genet Dev. 2012.

  40. Henikoff S, Shilatifard A. Histone modification: cause or cog? Trends Genet. 2011;27:389–96.

    PubMed  CAS  Google Scholar 

  41. • Miao F, Gonzalo IG, Lanting L, Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem. 2004;279:18091–7. This manuscript was one of the first to examine the epigenetic control of metabolic memory.

    PubMed  CAS  Google Scholar 

  42. Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-κB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem. 2008;283:26771–81.

    PubMed  CAS  Google Scholar 

  43. Miao F, Wu X, Zhang L, Yuan YC, Riggs AD, Natarajan R. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem. 2007;282:13854–63.

    PubMed  CAS  Google Scholar 

  44. Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R. Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes. 2008;57:3189–98.

    PubMed  CAS  Google Scholar 

  45. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R. Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U S A. 2008;105:9047–52.

    PubMed  CAS  Google Scholar 

  46. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009;58:1229–36.

    PubMed  CAS  Google Scholar 

  47. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409–17.

    PubMed  CAS  Google Scholar 

  48. •• Zhong Q, Kowluru RA. Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes. 2011;60:1304–13. This manuscript documents the complex control of gene expression through histone modification and illustrates the need for caution when examining individual histone modifications.

    PubMed  CAS  Google Scholar 

  49. Pirola L, Balcerczyk A, Tothill RW, Haviv I, Kaspi A, Lunke S, et al. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Res. 2011;21:1601–15.

    PubMed  CAS  Google Scholar 

  50. Rando OJ. Combinatorial complexity in chromatin structure and function: revisiting the histone code. Curr Opin Genet Dev. 2012;22:148–55.

    PubMed  CAS  Google Scholar 

  51. Yu J, Auwerx J. Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation. Pharmacol Res. 2010;62:35–41.

    PubMed  CAS  Google Scholar 

  52. •• Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 2012;61:217–28. It has become clear that the molecular machinery that modifies histones also has other substrates. This manuscript shows that modulating one of these enzymes has benefit for hyperglycemia induced changes other than histon modification.

    PubMed  CAS  Google Scholar 

  53. Vahtola E, Louhelainen M, Forsten H, Merasto S, Raivio J, Kaheinen P, et al. Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat. Cardiovasc Diabetol. 2010;9:5.

    PubMed  Google Scholar 

  54. Advani A, Wiggins KJ, Cox AJ, Zhang Y, Gilbert RE, Kelly DJ. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton). 2011;16:573–81.

    Google Scholar 

  55. Gilbert RE, Huang Q, Thai K, Advani SL, Lee K, Yuen DA, et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int. 2011;79:1312–21.

    PubMed  CAS  Google Scholar 

  56. Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat. 2009;117:443–51.

    PubMed  CAS  Google Scholar 

  57. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res. 2012;93:583–93.

    PubMed  CAS  Google Scholar 

  58. Liang R, Bates DJ, Wang E. Epigenetic control of microRNA expression and aging. Curr Genomics. 2009;10:184–93.

    PubMed  CAS  Google Scholar 

  59. Wu JH, Gao Y, Ren AJ, Zhao SH, Zhong M, Peng YJ, et al. Altered microRNA expression profiles in retinas with diabetic retinopathy. Ophthalmic Res. 2012;47:195–201.

    PubMed  CAS  Google Scholar 

  60. Kovacs B, Lumayag S, Cowan C, Xu S. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2011;52:4402–9.

    PubMed  CAS  Google Scholar 

  61. Esguerra JL, Bolmeson C, Cilio CM, Eliasson L. Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat. PLoS One. 2011;6:e18613.

    PubMed  CAS  Google Scholar 

  62. Wijesekara N, Zhang LH, Kang MH, Abraham T, Bhattacharjee A, Warnock GL, et al. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes. 2012;61:653–8.

    PubMed  CAS  Google Scholar 

  63. Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS, Matschinsky F, et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci U S A. 2011;108:12030–5.

    PubMed  CAS  Google Scholar 

  64. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–53.

    PubMed  CAS  Google Scholar 

  65. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci U S A. 2011;108:21075–80.

    PubMed  CAS  Google Scholar 

  66. Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H, et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem. 2011;351:197–205.

    PubMed  CAS  Google Scholar 

  67. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem. 2011;286:11837–48.

    PubMed  CAS  Google Scholar 

  68. Dey N, Das F, Mariappan MM, Mandal CC, Ghosh-Choudhury N, Kasinath BS, et al. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem. 2011;286:25586–603.

    PubMed  CAS  Google Scholar 

  69. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol. 2006;17:2484–94.

    PubMed  CAS  Google Scholar 

  70. Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, et al. miR-200a Prevents renal fibrogenesis through repression of TGF-beta2 expression. Diabetes. 2011;60:280–7.

    PubMed  CAS  Google Scholar 

  71. •• Putta S, Lanting L, Sun G, Lawson G, Kato M, Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012;23:458–69. This manuscript documents a potential therapeutic benefit by modulating miRNA expression.

    PubMed  CAS  Google Scholar 

  72. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104:3432–7.

    PubMed  CAS  Google Scholar 

  73. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011;60:1314–23.

    PubMed  CAS  Google Scholar 

  74. Feng B, Chen S, McArthur K, Wu Y, Sen S, Ding Q, et al. miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes. 2011;60:2975–84.

    PubMed  CAS  Google Scholar 

  75. Maunakea AK, Chepelev I, Zhao K, Bruneau B. Epigenome mapping in normal and disease States. Circ Res. 2010;107:327–39.

    PubMed  CAS  Google Scholar 

  76. Walsh CP, Bestor TH. Cytosine methylation and mammalian development. Genes Dev. 1999;13:26–34.

    PubMed  CAS  Google Scholar 

  77. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001;293:1089–93.

    PubMed  CAS  Google Scholar 

  78. Zilberman D, Gehring M, Tran RK, Ballinger T, Henikoff S. Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat Genet. 2007;39:61–9.

    PubMed  CAS  Google Scholar 

  79. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992;69:915–26.

    PubMed  CAS  Google Scholar 

  80. Chen T, Hevi S, Gay F, Tsujimoto N, He T, Zhang B, et al. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet. 2007;39:391–6.

    PubMed  CAS  Google Scholar 

  81. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315–22.

    PubMed  CAS  Google Scholar 

  82. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol. 2009;27:361–8.

    PubMed  CAS  Google Scholar 

  83. Laurent L, Wong E, Li G, Huynh T, Tsirigos A, Ong CT, et al. Dynamic changes in the human methylome during differentiation. Genome Res. 2010;20:320–31.

    PubMed  CAS  Google Scholar 

  84. Suzuki MM, Kerr AR, De SD, Bird A. CpG methylation is targeted to transcription units in an invertebrate genome. Genome Res. 2007;17:625–31.

    PubMed  CAS  Google Scholar 

  85. Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol. 2004;11:1068–75.

    PubMed  CAS  Google Scholar 

  86. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466:253–7.

    PubMed  CAS  Google Scholar 

  87. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008;9:465–76.

    PubMed  CAS  Google Scholar 

  88. Zemach A, McDaniel IE, Silva P, Zilberman D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science. 2010;328:916–19.

    PubMed  CAS  Google Scholar 

  89. Laird PW. Cancer epigenetics. Hum Mol Genet. 2005;14(Spec No 1):R65–76.

    PubMed  CAS  Google Scholar 

  90. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005;74:481–514.

    PubMed  CAS  Google Scholar 

  91. Watanabe Y, Maekawa M. Methylation of DNA in cancer. Adv Clin Chem. 2010;52:145–67.

    PubMed  CAS  Google Scholar 

  92. Casaccia-Bonnefil P, Pandozy G, Mastronardi F. Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis. Prog Neurobiol. 2008;86:368–78.

    PubMed  CAS  Google Scholar 

  93. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging. 2011;32:1161–80.

    PubMed  CAS  Google Scholar 

  94. Morgan HD, Sutherland HG, Martin DI, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet. 1999;23:314–8.

    PubMed  CAS  Google Scholar 

  95. Park JH, Stoffers DA, Nicholls RD, Simmons RA. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest. 2008;118:2316–24.

    PubMed  CAS  Google Scholar 

  96. Ling C, Del GS, Lupi R, Ronn T, Granhall C, Luthman H, et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia. 2008;51:615–22.

    PubMed  CAS  Google Scholar 

  97. Caramori ML, Kim Y, Moore JH, Rich SS, Mychaleckyj JC, Kikyo N, et al. Gene expression differences in skin fibroblasts in identical twins discordant for type 1 diabetes. Diabetes. 2012;61:739–44.

    PubMed  CAS  Google Scholar 

  98. Zhao J, Goldberg J, Bremner JD, Vaccarino V. Global DNA methylation is associated with insulin resistance: a monozygotic twin study. Diabetes. 2012;61:542–6.

    PubMed  CAS  Google Scholar 

  99. Sapienza C, Lee J, Powell J, Erinle O, Yafai F, Reichert J, et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics. 2011;6:20–8.

    PubMed  CAS  Google Scholar 

  100. Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, et al. Detection of beta cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A. 2011;108:19018–23.

    PubMed  CAS  Google Scholar 

  101. Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, et al. Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet. 2012;21:371–83.

    PubMed  CAS  Google Scholar 

  102. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, et al. Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genet. 2011;7:e1002300.

    PubMed  CAS  Google Scholar 

  103. Volkmar M, Dedeurwaerder S, Cunha DA, Ndlovu MN, Defrance M, Deplus R, et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. EMBO J. 2012;31:1405–26.

    PubMed  CAS  Google Scholar 

  104. Williams KT, Garrow TA, Schalinske KL. Type I diabetes leads to tissue-specific DNA hypomethylation in male rats. J Nutr. 2008;138:2064–69.

    PubMed  CAS  Google Scholar 

  105. • Williams KT, Schalinske KL. Tissue-specific alterations of methyl group metabolism with DNA hypermethylation in the Zucker (type 2) diabetic fatty rat. Diabetes Metab Res Rev. 2012;28:123–31. This manuscript was the first to show hyperglycemia induced DNA methylation changes.

    PubMed  CAS  Google Scholar 

  106. Olsen AS, Sarras Jr MP, Intine RV. Limb regeneration is impaired in an adult zebrafish model of diabetes mellitus. Wound Repair Regen. 2010;18:532–42.

    PubMed  Google Scholar 

  107. Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB, et al. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res. 2011;30:41.

    PubMed  CAS  Google Scholar 

  108. Santos JM, Mohammad G, Zhong Q, Kowluru RA. Diabetic retinopathy, superoxide damage and antioxidants. Curr Pharm Biotechnol. 2011;12:352–61.

    PubMed  CAS  Google Scholar 

  109. Kowluru RA, Mohammad G, dos Santos JM, Zhong Q. Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes. 2011;60:3023–33.

    PubMed  CAS  Google Scholar 

  110. Mohammad G, Kowluru RA. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:3832–41.

    PubMed  CAS  Google Scholar 

  111. Santos JM, Tewari S, Goldberg AF, Kowluru RA. Mitochondrial biogenesis and the development of diabetic retinopathy. Free Radic Biol Med. 2011;51:1849–60.

    PubMed  CAS  Google Scholar 

  112. Zhong Q, Kowluru RA. Diabetic retinopathy and damage to mitochondrial structure and transport machinery. Invest Ophthalmol Vis Sci. 2011;52:8739–46.

    PubMed  CAS  Google Scholar 

  113. Santos JM, Kowluru RA. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Invest Ophthalmol Vis Sci. 2011;52:8791–8.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by a research grant from the Iacocca Family Foundation, and National Institutes of Health Grant DK092721 (to R.V.I.). The authors thank Nikki Intine for aid in manuscript preparation.

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Dr. William M. Scholl College of Podiatric Medicine, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd, Rm L. 408, North Chicago, IL, 60064, USA

    Robert V. Intine

  2. Department of Cell, Biology, and Anatomy, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

    Robert V. Intine & Michael P. Sarras Jr.

Authors
  1. Robert V. Intine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Sarras Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert V. Intine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Intine, R.V., Sarras, M.P. Metabolic Memory and Chronic Diabetes Complications: Potential Role for Epigenetic Mechanisms. Curr Diab Rep 12, 551–559 (2012). https://doi.org/10.1007/s11892-012-0302-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-012-0302-7

Keywords

Search

Navigation